资讯

FDA approves Sanofi and Regeneron’s Dupixent for bullous pemphigoid
The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for ...
FDA approves Dupixent for bullous pemphigoid
The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.
Managed Healthcare Executive21 小时
Plans Agree to Prior Auth Reform. Physicians and Business Groups Want Measurable Results
More than 50 insurers have pledged to streamline and simplify the prior authorization process through six new commitments.